Overview
Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use. Lincomycin was approved by the FDA on December 29, 1964.
Indication
Lincomycin is indicated for the treatment of serious bacterial infections by susceptible strains of streptococci, pneumococci, and staphylococci in patients who are allergic to penicillins or for situations in which a penicillin is deemed inappropriate. As with all antibacterial agents, lincomycin should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.
Associated Conditions
- Serious Bacterial Infection
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2011/10/25 | Phase 2 | Completed | Aatif Husain | ||
2010/01/29 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Pharmacia & Upjohn Company LLC | 0009-0555 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 3/14/2024 | |
| Armas Pharmaceuticals Inc. | 72485-115 | INTRAVENOUS, INTRAMUSCULAR | 3000 mg in 10 mL | 5/18/2023 | |
| Slate Run Pharmaceuticals, LLC | 70436-035 | INTRAVENOUS, INTRAMUSCULAR | 300 mg in 1 mL | 1/24/2023 | |
| Pharmacia & Upjohn Company LLC | 0009-0104 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 3/14/2024 | |
| Armas Pharmaceuticals Inc. | 72485-114 | INTRAVENOUS, INTRAMUSCULAR | 600 mg in 2 mL | 5/18/2023 | |
| Pharmacia & Upjohn Company LLC | 0009-0107 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 3/14/2024 | |
| XGen Pharmaceuticals DJB, Inc. | 39822-0350 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 10/14/2022 | |
| XGen Pharmaceuticals DJB, Inc. | 39822-0353 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 10/14/2022 | |
| Slate Run Pharmaceuticals, LLC | 70436-034 | INTRAVENOUS, INTRAMUSCULAR | 300 mg in 1 mL | 1/24/2023 | |
| Gland Pharma Limited | 68083-479 | INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL | 300 mg in 1 mL | 9/28/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| LINCOMYCIN INJECTION 300 mg/ml | SIN01866P | INJECTION | 300 mg/ml | 6/18/1988 | |
| LINCOMYCIN INJECTION 300 mg/ml | SIN06683P | INJECTION | 300 mg/ml | 11/20/1991 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| LINCOMYCIN SXP lincomycin (as hydrochloride monohydrate) 300 mg/mL solution for injection ampoule | 281299 | Medicine | A | 12/4/2017 | |
| LINCOMYCIN SXP lincomycin (as hydrochloride monohydrate) 600 mg/2mL solution for injection ampoule | 281302 | Medicine | A | 12/4/2017 | |
| LINCOMYCIN LWS lincomycin (as hydrochloride monohydrate) 600 mg/2mL solution for injection ampoule | 281301 | Medicine | A | 12/4/2017 | |
| LINCOCIN lincomycin 600 mg/2 mL (as hydrochloride) injection vial | 12281 | Medicine | A | 8/2/1991 | |
| LINCOMYCIN LWS lincomycin (as hydrochloride monohydrate) 300 mg/mL solution for injection ampoule | 281300 | Medicine | A | 12/4/2017 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.